Leithner K - Search Results

1

Leithner K. Leithner K. Oncoscience. 2015 Sep 23;2(10):805-6. doi: 10.18632/oncoscience.252. eCollection 2015. Oncoscience. 2015. PMID: 26682254 Free PMC article. No abstract available.

2

Gluconeogenesis in cancer cells - Repurposing of a starvation-induced metabolic pathway?

Grasmann G, Smolle E, Olschewski H, Leithner K. Grasmann G, et al. Among authors: leithner k. Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):24-36. doi: 10.1016/j.bbcan.2019.05.006. Epub 2019 May 30. Biochim Biophys Acta Rev Cancer. 2019. PMID: 31152822 Free PMC article. Review.

3

No erythropoietin-induced growth is observed in non-small cell lung cancer cells.

Frille A, Leithner K, Olschewski A, Olschewski H, Wohlkönig C, Hrzenjak A. Frille A, et al. Among authors: leithner k. Int J Oncol. 2018 Feb;52(2):518-526. doi: 10.3892/ijo.2017.4225. Epub 2017 Dec 12. Int J Oncol. 2018. PMID: 29345289

4

Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.

Smolle E, Leithner K, Olschewski H. Smolle E, et al. Among authors: leithner k. Thorac Cancer. 2020 Feb;11(2):205-215. doi: 10.1111/1759-7714.13246. Epub 2019 Dec 4. Thorac Cancer. 2020. PMID: 31799812 Free PMC article. Review.

5

Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.

Leithner K, Stacher E, Wurm R, Ploner F, Quehenberger F, Wohlkoenig C, Bálint Z, Polachova J, Olschewski A, Samonigg H, Popper HH, Olschewski H. Leithner K, et al. Lung Cancer. 2009 Jul;65(1):98-104. doi: 10.1016/j.lungcan.2008.10.015. Epub 2008 Dec 9. Lung Cancer. 2009. PMID: 19081160

6

Gluconeogenesis in cancer: door wide open.

Leithner K, Hrzenjak A, Olschewski H. Leithner K, et al. Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4394. doi: 10.1073/pnas.1415680111. Epub 2014 Sep 26. Proc Natl Acad Sci U S A. 2014. PMID: 25261555 Free PMC article. No abstract available.

7

Metabolic heterogeneity in cancer.

Demicco M, Liu XZ, Leithner K, Fendt SM. Demicco M, et al. Among authors: leithner k. Nat Metab. 2024 Jan;6(1):18-38. doi: 10.1038/s42255-023-00963-z. Epub 2024 Jan 24. Nat Metab. 2024. PMID: 38267631 Review.

8

Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells.

Wohlkoenig C, Leithner K, Deutsch A, Hrzenjak A, Olschewski A, Olschewski H. Wohlkoenig C, et al. Among authors: leithner k. Cancer Lett. 2011 Sep 28;308(2):134-43. doi: 10.1016/j.canlet.2011.03.014. Epub 2011 Jun 12. Cancer Lett. 2011. PMID: 21669489

9

PCK2 activation mediates an adaptive response to glucose depletion in lung cancer.

Leithner K, Hrzenjak A, Trötzmüller M, Moustafa T, Köfeler HC, Wohlkoenig C, Stacher E, Lindenmann J, Harris AL, Olschewski A, Olschewski H. Leithner K, et al. Oncogene. 2015 Feb 19;34(8):1044-50. doi: 10.1038/onc.2014.47. Epub 2014 Mar 17. Oncogene. 2015. PMID: 24632615

10

Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.

Fischer C, Leithner K, Wohlkoenig C, Quehenberger F, Bertsch A, Olschewski A, Olschewski H, Hrzenjak A. Fischer C, et al. Among authors: leithner k. Mol Cancer. 2015 Jan 21;14:4. doi: 10.1186/1476-4598-14-4. Mol Cancer. 2015. PMID: 25608569 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68 results

Search Page